SCHEMBL4332440

SCHEMBL4332440

Cn1c(CBr)cc(=O)n1C1CCCCC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.35
PARP1 P09874 2/20 0.33
PARP2 Q9UGN5 2/20 0.33
GSK3A P49840 2/20 0.33
GSK3B P49841 2/20 0.33
PARP3 Q9Y6F1 1/20 0.33
ALOX15 P16050 1/20 0.33
ALDH1A1 P00352 7/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
PKM P14618 1/20 0.32
CYP3A4 P08684 1/20 0.32
KMT2A Q03164 1/20 0.32
MAPK1 P28482 1/20 0.32
NR1I2 O75469 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4318546 0.75 ALDH1A1 (0.41) TSHRPARP1PARP2GSK3AGSK3B
SCHEMBL4331843 0.73 NAPRT (0.39) TSHRPARP1PARP2GSK3AGSK3B
SCHEMBL4322668 0.69 PARP1 (0.36) PARP1PARP2GSK3AGSK3BPARP3
SCHEMBL4324545 0.68 CNR2 (0.35) PARP1PARP2GSK3AGSK3BPARP3
SCHEMBL4322764 0.67 TSHR (0.38) TSHRGSK3AGSK3BALOX15ALDH1A1
SCHEMBL4329240 0.66 KDM4E (0.35) TSHRPARP1PARP2GSK3AGSK3B
SCHEMBL4326610 0.66 CNR2 (0.33) PARP1PARP2PARP3ALDH1A1MAPT
SCHEMBL4327972 0.64 KDM4E (0.33) TSHRPARP1PARP2ALOX15ALDH1A1
SCHEMBL4323167 0.62 SMURF1 (0.41) PARP1PARP2MAPK1
SCHEMBL4324410 0.60 SMURF1 (0.39) PARP1PARP2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069340-A1 Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders ASTRAZENECA AB (SE) 2009-03-12 US disclosed
EP-1833800-A1 PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006071730-A1 PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS ASTRAZENECA AB (SE) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069340-A1 Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders GRIN1, GRM1, GRIN3A TSHR 240/4885PARP1 3649/4885PARP2 4559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.